- Home
- IFRX vs ANL Comparison
IFRX vs ANL Comparison
Compare IFRX & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IFRX
- ANL
- Stock Information
- Founded
- IFRX 2007
- ANL 2004
- Country
- IFRX Germany
- ANL Cayman Islands
- Employees
- IFRX N/A
- ANL N/A
- Industry
- IFRX Biotechnology: Pharmaceutical Preparations
- ANL
- Sector
- IFRX Health Care
- ANL
- Exchange
- IFRX Nasdaq
- ANL Nasdaq
- Market Cap
- IFRX 53.5M
- ANL 61.8M
- IPO Year
- IFRX 2017
- ANL 2023
- Fundamental
- Price
- IFRX $1.27
- ANL $1.68
- Analyst Decision
- IFRX Strong Buy
- ANL Hold
- Analyst Count
- IFRX 5
- ANL 1
- Target Price
- IFRX $7.40
- ANL N/A
- AVG Volume (30 Days)
- IFRX 486.5K
- ANL 9.2K
- Earning Date
- IFRX 11-07-2025
- ANL 10-31-2025
- Dividend Yield
- IFRX N/A
- ANL N/A
- EPS Growth
- IFRX N/A
- ANL N/A
- EPS
- IFRX N/A
- ANL N/A
- Revenue
- IFRX $191,224.00
- ANL N/A
- Revenue This Year
- IFRX N/A
- ANL N/A
- Revenue Next Year
- IFRX $1,216.24
- ANL N/A
- P/E Ratio
- IFRX N/A
- ANL N/A
- Revenue Growth
- IFRX 54.36
- ANL N/A
- 52 Week Low
- IFRX $0.71
- ANL $1.10
- 52 Week High
- IFRX $2.82
- ANL $3.89
- Technical
- Relative Strength Index (RSI)
- IFRX 47.77
- ANL 48.38
- Support Level
- IFRX $1.14
- ANL $1.60
- Resistance Level
- IFRX $1.44
- ANL $1.73
- Average True Range (ATR)
- IFRX 0.14
- ANL 0.08
- MACD
- IFRX -0.03
- ANL -0.01
- Stochastic Oscillator
- IFRX 26.00
- ANL 47.94
About IFRX InflaRx N.V.
InflaRx NV is a clinical-stage biopharmaceutical company focused on applying proprietary anti-C5a/C5aR technology to discover and develop first-in-class, potent, and specific inhibitors of the complement activation factor known as C5a and its receptor known as C5aR. C5a is an inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. Its product candidate, vilobelimab, is a novel intravenously delivered first-in-class anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.